Ladenburg analyst Matthew Kaplan raised the firm’s price target on TG Therapeutics to $37.50 from $26 and keeps a Buy rating on the shares, stating that its higher target is based on the "strong launch" and updated revenue projections for Briumvi following the company’s Q1 report, calling sales for the first partial quarter "impressive."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TGTX:
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- TG Therapeutics price target raised to $34 from $28 at H.C. Wainwright
- TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
- TG Therapeutics reports Q1 EPS (28c), consensus (37c)
- TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
